Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 21, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for December 28, 2007 Subscribe to this News Feed     Subscribe to this Podcast Feed  
 

Red Wine Resveratrol -- In Quest Of An Anti-Aging Pill, 2007 In Review

Advancements toward an anti-aging pill continue to unfold, but will such a pill ever be adopted by modern medicine, and will the masses ever use it? Bill Sardi writes a review of the progress made in 2007 toward technology that promises to slow aging.

(PRWEB) December 28, 2007 -- What a year in the anti-aging field. Leonard Hayflick, whose "Hayflick limit" suggests a limit on the number of times a cell can replicate may limit the theoretical length of human life, now says "biological aging is no longer an unsolved problem."

Also in 2007, Aubrey de Grey and Michael Rae authored Endless Aging (St. Martin's Press, 2007) which described a theory of aging, that the inability of aged cells to eliminate cellular debris and to produce energy, is why humans age.

biological aging is no longer an unsolved problem.
David Sinclair PhD, the Harvard professor who discovered that a red wine molecule, resveratrol, acts as a molecular mimic of calorie restriction via its ability to activate the Sirtuin 1 gene, continues to amaze with this discoveries of even more powerful gene-activating molecules. Sinclair himself isn't waiting for more research. He has begun taking red wine pills in the hopes of slowing the aging process in his body.

Will humans commonly live 120 years and beyond, beginning anytime soon? "If red wine pills do slow the aging process, the public hasn't responded to the news headlines. Resveratrol pills aren't in the top 100 selling herbal supplements," say Bill Sardi, of Resveratrol Partners LLC (dba Longevinex®).

Even if red wine resveratrol pills were proven to slow the aging process, many users wouldn't have achieved any benefit because, as a 2007 report by ConsumerLab revealed, two major brands of resveratrol that have been sold for the past three years didn't have any appreciable amount of resveratrol in their pills. The quality of resveratrol dietary supplements remains highly variable. "Consumers of these impotent pills should be demanding refunds," says Sardi.

How much resveratrol?
Why aren't more Americans taking red wine pills? Some may have opted to drink red wine, which is not a reliable source of resveratrol. Others may have been misdirected. "Errant advice suggests consumers would have to consume over a thousand bottles of red wine, or more than 100 red wine pills, to achieve the beneficial effects seen in recent animal studies, so the public backed off of the idea," says Sardi.

After a mouse study suggested a dose of resveratrol exceeding 1500 milligrams might be needed to overcome the adverse effects of a high-fat diet, some people began taking supra-high doses of resveratrol, and some have begun to experience side effects. A study published in 2007 shows that a single high-dose (500-5000 milligrams) of resveratrol can produce reversible side effects. Forty volunteers taking high-dose resveratrol supplements experienced 51 side effects, 12 side effects being reported at the lowest (500 mg) dose. "Until more is known about its use in humans, it's best to enhance the bioavailability of resveratrol with quercetin than to take supra-high doses," says Sardi.

First successful human study
The first successful human study of resveratrol was reported in 2007. Researchers at Appalachian State University found that Longevinex®, a dietary supplement providing a unique combination of resveratrol, quercetin and rice bran, significantly reduced markers of inflammation and oxidation in endurance athletes.

Age-slowing drugs in the near future?
What about a resveratrol-like drug, which is reported to activate the Sirtuin 1 DNA-repair "survival" gene 1000-fold greater than resveratrol itself? "When this drug receives FDA approval there will be such a demand for it to treat age-related diseases, cardiologists, oncologists, ophthalmologists, brain surgeons and other doctors will be clamoring for it, and it will generate so much profit (likely to become the first $100 billion drug!) that its promise to slow the aging process is likely to be forgotten," says Sardi.

One might think that the public would be chomping at the bit to take a pill that might make it possible to live 100 years. A recent survey indicates 4 in 10 Britons would give up favorite things, like sex, travel or food and drinks, in order reach the age of 100 years. But 3 of 4 Britons say they would not part with their money to achieve this goal.

To read the entire report, In Quest Of An Anti-Aging Pill, 2007 In Review, please visit www.longevinex.com

This press release is a copyrighted. Publication only permitted at PRWeb. ©2007 Resveratrol Partners LLC

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U2luZy1Mb3ZlLVN1bW0tRW1wdC1Mb3ZlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
WILLIAM SARDI
Resveratrol Partners LLC
909 596 9507
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright